1-13 of 13
John Catalano, MBBS, FRACP, FRCPA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa

Catherine Thieblemont, MD PhD, Maria Gomes da Silva, MD, Olivier Casasnovas, MD, Hervé Ghesquieres, MD PhD, Gandhi Laurent Damaj, MD PhD, Judith Trotman, FRACP, Pierre Feugier, MD PhD, Corinne Haioun, MDPhD, Richard Greil, MD, Dolores Caballero, MD PhD, Armando Lopez-Guillermo, Sebastian Grosicki, MD PhD, Koen Van Eygen, MD, Sylvia Snauwaert, MD, Ewa Lech-Marańda, MD PhD, Sonja Heibl, MD, John Catalano, MBBS, FRACP, FRCPA, Amos Cohen, MD, Anne Cairoli, MD, Philippe Gaulard, MD PhD, Franck Morschhauser, MD PhD, Herve Tilly, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-136511
Published: 2020
Journal Articles

Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib

Ruben A Mesa, MD, John Catalano, MBBS, FRACP, FRCPA, Francisco Cervantes, MD, Timothy Devos, MD PhD, Jason Gotlib, MD MS, Jean-Jacques Kiladjian, MD PhD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Kazuya Shimoda, MD PhD, Elisabeth Coart, PhD, Koenraad D'Hollander, MD MSC, Rafe Donahue, PhD, Mark M Kowalski, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1663.
https://doi.org/10.1182/blood-2019-122506
Published: 2019
Journal Articles

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

Gilles Andre Salles, MD, PhD, John Francis Seymour, MBBS, FRACP, PhD, Pierre Feugier, MD, PhD, Fritz Offner, MD, Armando Lopez-Guillermo, MD, PhD, David Belada, M.D., Ph.D., Luc Xerri, MD, PhD, Reda Bouabdallah, MD, John Catalano, MBBS FRACP FRCPA, Brice Pauline, MD, Dolores Caballero, MD, PhD, Corinne Haioun, MD, PhD, Lars Moller Pedersen, Alain Delmer, MD, David Simpson, Sirpa Leppa, Pierre Soubeyran, Anton Hagenbeek, MD, PhD, Olivier Casasnovas, MD, Tanin Intragumtornchai, MD, Christophe Ferme, MD, Maria Gomes da Silva, Catherine Sebban, MD, Andrew Lister, Jane A Estell, MBBS, FRCPA, FRACP, Gustavo Milone, Anne Sonet, MD, Bertrand Coiffier, MD, PhD, Herve Tilly, MD
Journal: Blood
Blood (2013) 122 (21): 509.
https://doi.org/10.1182/blood.V122.21.509.509
Published: 2013
Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Annika Dufour, Stefan K Bohlander, Evelyn Zellmeier, Gudrun Mellert, Karsten Spiekermann, MD, Stephanie Schneider, PhD, Purvi Kakadia, Wolfgang Hiddemann, PhD, Jan Braess, Sim Truong, Nancy Patten, Lin Wu, Galina Salogub, Philippe Solal-Celigny, Anna Dmoszynska, Tadeusz Robak, Boris V Afanasiev, Marco Montillo, John Catalano, MBBS FRACP FRCPA, Christian H. Geisler, David Dornan, Ming Lin, Ru-Fang Yeh, Martin Weisser, Guillemette Duchateau-Nguyen, Giuseppe Palermo
Journal: Blood
Blood (2011) 118 (21): 2445.
https://doi.org/10.1182/blood.V118.21.2445.2445
Published: 2011
Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Annika Dufour, PhD, Stefan K Bohlander, Evelyn Zellmeier, Gudrun Mellert, Karsten Spiekermann, MD, Stephanie Schneider, PhD, Purvi Kakadia, Wolfgang Hiddemann, PhD, Jan Braess, Sim Truong, Nancy Patten, Lin Wu, Galina Salogub, Philippe Solal-Celigny, Anna Dmoszynska, Tadeusz Robak, Boris V Afanasiev, Marco Montillo, John Catalano, MBBS FRACP FRCPA, Christian H. Geisler, David Dornan, Ming Lin, Ru-Fang Yeh, Martin Weisser, Guillemette Duchateau-Nguyen, Giuseppe Palermo
Journal: Blood
Blood (2011) 118 (21): 3521.
https://doi.org/10.1182/blood.V118.21.3521.3521
Published: 2011
Journal Articles

A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms

Huyen Tran, MBBS, MSc, FRACP, FRCPA, Jamie P Nourse, PhD, Rod Lea, PhD, Timothy A. Brighton, FRCPA, FRACP, MB, BS, MS, Andrew Grigg, MBBS, FRACP, FRCPA, Simon McRae, BMedSc, MBBS, FRACP, FRCPA, Daniel Thurley, MA, MB, BCHIR, Dep. pharm. med, MRCP, FFPM, Maher Gandhi, PhD, FRACP, FRCPath, FRCP, John Catalano, MBBS FRACP FRCPA
Journal: Blood
Blood (2011) 118 (21): 1157.
https://doi.org/10.1182/blood.V118.21.1157.1157
Published: 2011
Journal Articles

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015

Antonio Palumbo, MD, Zdenek Adam, Martin Kropff, MD, Robin Foà, John Catalano, MBBS FRACP FRCPA, Heinz Gisslinger, MD, Wieslaw Wiktor-Jedrzejczak, MD, PhD, Michel Delforge, MD, PhD, Katja Weisel, MD, Nicola Cascavilla, MD, Jan Van Droogenbroeck, Genadi Iosava, MD, Michele Cavo, MD, Joan Blade, Meral Beksac, MD, Ivan Spicka, MD, PhD, Torben Plesner, MD, Zhinuan Yu, Lindsey Herbein, Jay Mei, MD, PhD, Christian J. Jacques, Meletios Athanasios Dimopoulos, MD
Journal: Blood
Blood (2011) 118 (21): 475.
https://doi.org/10.1182/blood.V118.21.475.475
Published: 2011
Journal Articles

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

Andrew H Wei, MBBS, PhD, Sonali Sadawarte, John Catalano, MBBS, FRACP, FRCPA, Robert Hills, MA, MSc, DPhil, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, Alan Burnett, Andrew Spencer, MD
Journal: Blood
Blood (2010) 116 (21): 3299.
https://doi.org/10.1182/blood.V116.21.3299.3299
Published: 2010
Journal Articles

Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study

Andrew H Wei, MBBS, PhD, Sonali Sadawarte, MBBS, MD, DM, John Catalano, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, Andrew Spencer, MD
Journal: Blood
Blood (2010) 116 (21): 3301.
https://doi.org/10.1182/blood.V116.21.3301.3301
Published: 2010
Journal Articles

Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.

Gilles Andre Salles, MD, PhD, John Catalano, MBBS, FRACP, FRCPA, Pierre Feugier, MD, PhD, Fritz C Offner, MD, PhD, Reda Bouabdallah, MD, Dolores Caballero, MD, Pauline Brice, MD, Lars Moller Pedersen, MD, Corinne Haioun, MD, David Belada, MD, Alain Delmer, MD, David Simpson, FRACP, FRCPA, MB, CHB, Herve Tilly, MD, Sirpa Leppa, MD, Pierre Soubeyran, MD, Anton Hagenbeek, MD, PhD, Olivier Casasnovas, MD, Tanin Intragumtornchai, MD, MSc, Christophe Fermé, MD, Maria Gomes da Silva, MD, Catherine Sebban, MD, Andrew Lister, MD, Jane A Estell, MBBS, FRCPA, FRACP, Gustavo Milone, MD, Anne Sonet, MD, Armando Lopez-Guillermo, MD, John Francis Seymour, MBBS, FRACP, Ph, D, Luc Xerri, MD
Journal: Blood
Blood (2010) 116 (21): 1788.
https://doi.org/10.1182/blood.V116.21.1788.1788
Published: 2010
Journal Articles

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens

Antonio Palumbo, MD, Michel Delforge, MD, PhD, John Catalano, MBBS, FRACP, FRCPA, Roman Hajek, MD, PhD, Martin Kropff, MD, Maria Teresa Petrucci, Zhinuan Yu, Lindsey Herbein, Jay M. Mei, MD, PhD, Christian J. Jacques, MD, Meletios A. Dimopoulos
Journal: Blood
Blood (2010) 116 (21): 622.
https://doi.org/10.1182/blood.V116.21.622.622
Published: 2010
Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Annika Dufour, MD, S. K Bohlander, PhD, Karsten Spiekermann, MD, Stephanie Schneider, Jan Braess, MD, Purvi Kakadiya, Kirsten E Mundt, PhD, Helen Smith, Ming Lin, PhD, Martin Barrett, PhD, Deborah Hurst, MD, Anna Dmoszynska, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Boris V Afanasiev, MD, John Catalano, MBBS, FRACP, FRCPA, Marco Montillo, Christian H. Geisler, MD, Sergey I Moiseev, MD, Philippe Solal-Celigny, MD, Tadeusz Robak, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2010) 116 (21): 1390.
https://doi.org/10.1182/blood.V116.21.1390.1390
Published: 2010
Journal Articles

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Taimur Sher, MD, Jose Azar, MD, Stephen Spurgeon, MD, John Catalano, MBBS, FRACP, FRCPA, Richard R. Furman, MD, Miles Prince, MD, FRACP, FRCPA, Nancy L. Bartlett, MD, Simon Durrant, MBBS, FRCP, FRCPath, Ralph Boccia, MD, Aisha Masood, MD, Scott Lyman, MS, Jean Cantey-Kiser, William P Sheridan, MB, BS, Asher Chanan-Khan, MD
Journal: Blood
Blood (2010) 116 (21): 1397.
https://doi.org/10.1182/blood.V116.21.1397.1397
Published: 2010